should cellular therapies be moved to first line treatment? - blood cancer onctalk
Published 1 year ago • 19 plays • Length 3:40Download video MP4
Download video MP3
Similar videos
-
7:39
car t-cell versus bispecific therapies: how oncologists determine treatment - blood cancer onctalk
-
2:44
approaching treatment for smoldering multiple myeloma - blood cancer onctalk 2023
-
4:11
treatment options for newly diagnosed aml: venetoclax and midostaurin - blood cancer onctalk
-
6:28
q&a: should i change my myeloma treatment if i feel healthy? - blood cancer onctalk 2023
-
4:33
q&a: how successful are bone marrow transplants for lymphoma? - blood cancer onctalk 2023
-
2:28:27
vod 2023 blood cancer onctalk
-
3:12
what are the pros and cons of car t-cell therapy vs. bispecific antibodies? - blood cancer onctalk
-
6:45
approaches for treatment of multiple myeloma - blood cancer onctalk
-
7:55
what is a bone marrow transplant? - blood cancer onctalk 2023
-
3:01
is there a preference for type of car t-cell treatment? - blood cancer onctalk
-
1:31
are there any ongoing trials for acute leukemia in adults? - blood cancer onctalk
-
2:06
patient role in bispecific antibody treatment - blood cancer onctalk 2023
-
1:37
pros and cons of bispecific antibodies - blood cancer onctalk 2023
-
5:48
teclistamab, talquetamab, and elranatamab: response rates and data - blood cancer onctalk 2023
-
2:20:58
blood cancer onctalk february 2023 on demand
-
1:39
grace targeted therapies lung cancer 2021 - treatment after crizotinib in ros1 lung cancer
-
1:59:57
grace - global resource for advancing cancer education live stream
-
14:06
is there a place for telemedicine in oncology? - the evolving world of covid and cancer
-
8:06
advances in multiple myeloma: what is needed to get to a cure? - blood cancer onctalk